Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges associated with recruiting and monitoring patients in the current pandemic environment.

Conditions

COVID-19
Acute Respiratory Distress Syndrome (ARDS)

Interventions

DRUG: Razuprotafib Subcutaneous Solution
DRUG: Placebo Subcutaneous Solution

Sponsor

EyePoint Pharmaceuticals, Inc.